TRCT
ANTH

Tower Research Capital (TRC)’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Tower Research Capital (TRC)’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-172
Closed – – 4394
2017
Q3 		$0 Sell
172
-688
-80% -$977 ﹤0.01% 4384
2017
Q2 		$1K Sell
860
-1,718
-67% -$3.85K ﹤0.01% 2587
2017
Q1 		$9K Sell
2,578
-1,974
-43% -$9.33K ﹤0.01% 1893
2016
Q4 		$24K Buy
+4,552
New +$78.8K ﹤0.01% 1996
2016
Q1 		– Sell
-326
Closed -$12K – 5424
2015
Q4 		$12K Buy
326
+117
+56% +$5.16K ﹤0.01% 1947
2015
Q3 		$10K Sell
209
-873
-81% -$61K ﹤0.01% 2344
2015
Q2 		$75K Buy
+1,082
New +$50.1K 0.01% 1068
2015
Q1 		– Sell
-38
Closed – – 5235
2014
Q4 		$0 Buy
+38
New +$552 ﹤0.01% 5101
2014
Q1 		– Sell
-20
Closed – – 5232
2013
Q4 		$0 Buy
+20
New +$515 ﹤0.01% 5170
2013
Q3 		– Sell
-6
Closed – – 5029
2013
Q2 		$0 Buy
+6
New +$224 ﹤0.01% 4014

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Tower Research Capital (TRC)'s ANTH Position: Q4 2017 in Review

Tower Research Capital (TRC) sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2017, closing a stake of 172 shares.

Tower Research Capital (TRC) first reported a position in ANTH in Q2 2013 and held it in 10 quarters. The position peaked at $75K in Q2 2015. 37 funds tracked by Wall St. Rank hold ANTH as of Q4 2017.

  • Tower Research Capital (TRC) reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 172 Anthera Pharmaceuticals, Inc. shares in Q4 2017.
  • Tower Research Capital (TRC) first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Anthera Pharmaceuticals, Inc. position peaked at $75K in Q2 2015.
  • 37 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2017, filed 9 Feb 2018.